Clinical Microbiology Market Size, Share & Trends Analysis Report by Product (Laboratory Instruments, Reagents), Disease (STDs, Respiratory Diseases), Region, and Segment Forecasts, 2024-2030

The global clinical microbiology market size is anticipated to reach USD 6.60 billion by 2030, registering a CAGR of 5.35% from 2024 to 2030. Rising healthcare expenditure in developing countries, growing demand for rapid diagnostic tests, and high adoption of advanced molecular diagnostic techniques are the major factors contributing to market growth. According to the Centers for Medicare and Medicaid Service, U.S. healthcare spending grew 4.1% to reach USD 4.5 trillion in 2022, faster than the increase of 3.2% in 2021. Infectious diseases are primarily diagnosed using clinical tests.

According to the CDC, around 8,916 new cases of tuberculosis, 58,371 new cases of salmonella, 34,945 new cases of Lyme disease, and 371 new cases of meningococcal disease were registered in the U.S. in 2019. The American Cancer Society had estimated 1,958,310 new cancer cases with 609,820 cancer-related deaths in the U.S. in 2023. Thus, the constantly increasing prevalence of chronic diseases where clinical tests are used as one of the major diagnostic tools is expected to augment market growth. Sudden outbreaks of diseases, such as Ebola, Zika, and other contagious pathogens, are contributing to the rising prevalence of infectious diseases.

Moreover, as technology advances, molecular diagnostic technologies aid in early detection & effective treatment. These improved molecular diagnostic procedures indicate increased sample throughput, shorter turnaround times, increased specificity, accuracy, and higher reaction multiplicity. Furthermore, NGS, molecular cartridges, real-time PCR, and PCR+MS are advanced molecular diagnostic techniques that can analyze several samples in a single input. This chemical & pathogen characterization & identification enable product adaptation among important end-users, such as medical professionals, pharmaceutical & biotechnology businesses, and research centers.

This can provide an environment conducive to expanding the global market. The market faces several challenges, such as the increasing prevalence of drug-resistant pathogens, complex regulatory requirements, and need for specialized equipment & expertise. In developing countries, the need for proper laboratory infrastructure, trained personnel, and diagnostic equipment limits access to timely and accurate microbial testing. Limited funding and resources in healthcare systems hamper investments in advanced clinical microbiology technologies and personnel training.

Clinical Microbiology Market Report Highlights

The reagent product segment dominated the market with a share of over 72.20% in 2023 owing to prominent application in identifying different types of microorganisms
The laboratory instruments segment is expected to grow at the fastest CAGR from 2024 to 2030
The respiratory disease segment held the largest revenue share of 35.51% in 2023 due to high air pollution levels that can cause respiratory disease
The bloodstream infections segment is anticipated to witness significant CAGR from 2024 to 2030
North America dominated the global market with a share of 39.3% in 2023 owing to factors, such as the significant burden of infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.3. Estimates and forecasts timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased database
1.5.2. Internal database
1.5.3. Secondary sources
1.5.4. Primary research
1.5.5. Details of primary research
1.6. Information or Data Analysis
1.6.1. Data analysis models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity flow analysis (Model 1)
1.8.2. Approach 1: Commodity flow approach
1.9. List of Secondary Sources
1.10. List of Primary Sources
1.11. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights

Chapter 3. Clinical Microbiology Market Variables &Trends

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Technological advancements
3.2.1.2. Growing concern over infection control
3.2.1.3. Increasing prevalence of infectious diseases
3.2.2. Market restraint analysis
3.2.2.1. Limited access to testing facilities
3.3. Clinical Microbiology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

4.1. Global Clinical Microbiology Market by Product Outlook
4.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.3. Laboratory Instruments
4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Incubators
4.3.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Gram stainers
4.3.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Bacterial colony counters
4.3.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5. Autoclave sterilizers
4.3.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.6. Petri dish fillers
4.3.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Automated Culture System
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Microbiology analyzers
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Molecular diagnostic instruments
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Microscopes
4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. Mass spectrometers
4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Reagents
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Disease Business Analysis

5.1. Global Clinical Microbiology Market by Disease Outlook
5.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.3. Respiratory Diseases
5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Bloodstream Infection
5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Gastrointestinal Diseases
5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Sexually Transmitted Diseases (STDs)
5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Urinary Tract Infections
5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Periodontal Diseases
5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Other Diseases
5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

6.1. Regional Market Share Analysis, 2023 & 2030
6.2. North America
6.2.1. North America market estimates and forecasts, 2018 to 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key country dynamics
6.2.2.2. Regulatory framework
6.2.2.3. Competitive scenario
6.2.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
6.2.2.5. Target disease prevalence
6.2.3. Canada
6.2.3.1. Key country dynamics
6.2.3.2. Regulatory framework
6.2.3.3. Competitive scenario
6.2.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
6.2.3.5. Target disease prevalence
6.3. Europe
6.3.1. Europe market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework
6.3.2.3. Competitive scenario
6.3.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.2.5. Target disease prevalence
6.3.3. Germany
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework
6.3.3.3. Competitive scenario
6.3.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.3.5. Target disease prevalence
6.3.4. France
6.3.4.1. Key country dynamics
6.3.4.2. Regulatory framework
6.3.4.3. Competitive scenario
6.3.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.4.5. Target disease prevalence
6.3.5. Italy
6.3.5.1. Key country dynamics
6.3.5.2. Regulatory framework
6.3.5.3. Competitive scenario
6.3.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.5.5. Target disease prevalence
6.3.6. Spain
6.3.6.1. Key country dynamics
6.3.6.2. Regulatory framework
6.3.6.3. Competitive scenario
6.3.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.6.5. Target disease prevalence
6.3.7. Norway
6.3.7.1. Key country dynamics
6.3.7.2. Regulatory framework
6.3.7.3. Competitive scenario
6.3.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.7.5. Target disease prevalence
6.3.8. Sweden
6.3.8.1. Key country dynamics
6.3.8.2. Regulatory framework
6.3.8.3. Competitive scenario
6.3.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.8.5. Target disease prevalence
6.3.9. Denmark
6.3.9.1. Key country dynamics
6.3.9.2. Regulatory framework
6.3.9.3. Competitive scenario
6.3.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.9.5. Target disease prevalence
6.4. Asia Pacific
6.4.1. Asia Pacific market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework
6.4.2.3. Competitive scenario
6.4.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2.5. Target disease prevalence
6.4.3. China
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework
6.4.3.3. Competitive scenario
6.4.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3.5. Target disease prevalence
6.4.4. India
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework
6.4.4.3. Competitive scenario
6.4.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4.5. Target disease prevalence
6.4.5. Australia
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework
6.4.5.3. Competitive scenario
6.4.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5.5. Target disease prevalence
6.4.6. South Korea
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework
6.4.6.3. Competitive scenario
6.4.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6.5. Target disease prevalence
6.4.7. Thailand
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework
6.4.7.3. Competitive scenario
6.4.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.7.5. Target disease prevalence
6.5. Latin America
6.5.1. Latin America market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.2.5. Target disease prevalence
6.5.3. Mexico
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.3.5. Target disease prevalence
6.5.4. Argentina
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework
6.5.4.3. Competitive scenario
6.5.4.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.4.5. Target disease prevalence
6.6. MEA
6.6.1. MEA market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.2.5. Target disease prevalence
6.6.3. Saudi Arabia
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.3.5. Target disease prevalence
6.6.4. UAE
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.4.5. Target disease prevalence
6.6.5. Kuwait
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework
6.6.5.3. Competitive scenario
6.6.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.5.5. Target disease prevalence

Chapter 7. Competitive Landscape

7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. bioMérieux SA
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. BD
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Danaher
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Abbott
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Hologic, Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. F. Hoffmann-La Roche Ltd
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Bruker
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Bio-Rad Laboratories, Inc.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 North America clinical microbiology market, by region, 2018 - 2030 (USD Million)
Table 3 North America clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 4 North America clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 5 U.S. clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 6 U.S. clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 7 Canada clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 8 Canada clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 9 Europe clinical microbiology market, by region, 2018 - 2030 (USD Million)
Table 10 Europe clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 11 Europe clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 12 Germany clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 13 Germany clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 14 UK clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 15 UK clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 16 France clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 17 France clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 18 Italy clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 19 Italy clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 20 Spain clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 21 Spain clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 22 Denmark clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 23 Denmark clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 24 Sweden clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 25 Sweden clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 26 Norway clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 27 Norway clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 28 Asia Pacific clinical microbiology market, by region, 2018 - 2030 (USD Million)
Table 29 Asia Pacific clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 30 Asia Pacific clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 31 China clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 32 China clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 33 Japan clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 34 Japan clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 35 India clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 36 India clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 37 South Korea clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 38 South Korea clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 39 Australia clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 40 Australia clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 41 Thailand clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 42 Thailand clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 43 Latin America clinical microbiology market, by region, 2018 - 2030 (USD Million)
Table 44 Latin America clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 45 Latin America clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 46 Brazil clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 47 Brazil clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 48 Mexico clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 49 Mexico clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 50 Argentina clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 51 Argentina clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 52 MEA clinical microbiology market, by region, 2018 - 2030 (USD Million)
Table 53 MEA clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 54 MEA clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 55 South Africa clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 56 South Africa clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 59 UAE clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 60 UAE clinical microbiology market, by disease, 2018 - 2030 (USD Million)
Table 61 Kuwait clinical microbiology market, by product, 2018 - 2030 (USD Million)
Table 62 Kuwait clinical microbiology market, by disease, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Clinical microbiology market: market outlook
Fig. 9 Clinical microbiology competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Clinical microbiology market driver impact
Fig. 13 Clinical microbiology market restraint impact
Fig. 14 Clinical microbiology market: Product movement analysis
Fig. 15 Clinical microbiology market: Product outlook and key takeaways
Fig. 16 Laboratory instruments market estimates and forecast, 2018 - 2030
Fig. 17 Incubators market estimates and forecast, 2018 - 2030
Fig. 18 Gram stainers market estimates and forecast, 2018 - 2030
Fig. 19 Bacterial colony counters market estimates and forecast, 2018 - 2030
Fig. 20 Autoclave sterilizers market estimates and forecast, 2018 - 2030
Fig. 21 Petri dish fillers market estimates and forecast, 2018 - 2030
Fig. 22 Automated culture system market estimates and forecast, 2018 - 2030
Fig. 23 Microbiology analyzers market estimates and forecast, 2018 - 2030
Fig. 24 Molecular diagnostic instruments market estimates and forecast, 2018 - 2030
Fig. 25 Microscopes market estimates and forecast, 2018 - 2030
Fig. 26 Mass spectrometers market estimates and forecast, 2018 - 2030
Fig. 27 Reagents market estimates and forecast, 2018 - 2030
Fig. 28 Clinical microbiology Market: Disease movement Analysis
Fig. 29 Clinical microbiology market: Disease outlook and key takeaways
Fig. 30 Respiratory diseases market estimates and forecasts, 2018 - 2030
Fig. 31 Bloodstream infections market estimates and forecasts,2018 - 2030
Fig. 32 Gastrointestinal diseases market estimates and forecasts,2018 - 2030
Fig. 33 Sexually transmitted diseases market estimates and forecasts, 2018 - 2030
Fig. 34 Urinary tract infections market estimates and forecasts,2018 - 2030
Fig. 35 Periodontal diseases market estimates and forecasts,2018 - 2030
Fig. 36 Other diseases market estimates and forecasts,2018 - 2030
Fig. 37 Global clinical microbiology market: Regional movement analysis
Fig. 38 Global clinical microbiology market: Regional outlook and key takeaways
Fig. 39 North America market estimates and forecasts, 2018 - 2030
Fig. 40 U.S. key country dynamics
Fig. 41 U.S. market estimates and forecasts, 2018 - 2030
Fig. 42 Canada key country dynamics
Fig. 43 Canada market estimates and forecasts, 2018 - 2030
Fig. 44 Europe market estimates and forecasts, 2018 - 2030
Fig. 45 UK key country dynamics
Fig. 46 UK market estimates and forecasts, 2018 - 2030
Fig. 47 Germany key country dynamics
Fig. 48 Germany market estimates and forecasts, 2018 - 2030
Fig. 49 France key country dynamics
Fig. 50 France market estimates and forecasts, 2018 - 2030
Fig. 51 Italy key country dynamics
Fig. 52 Italy market estimates and forecasts, 2018 - 2030
Fig. 53 Spain key country dynamics
Fig. 54 Spain market estimates and forecasts, 2018 - 2030
Fig. 55 Denmark key country dynamics
Fig. 56 Denmark market estimates and forecasts, 2018 - 2030
Fig. 57 Sweden key country dynamics
Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
Fig. 59 Norway key country dynamics
Fig. 60 Norway market estimates and forecasts, 2018 - 2030
Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 62 China key country dynamics
Fig. 63 China market estimates and forecasts, 2018 - 2030
Fig. 64 Japan key country dynamics
Fig. 65 Japan market estimates and forecasts, 2018 - 2030
Fig. 66 India key country dynamics
Fig. 67 India market estimates and forecasts, 2018 - 2030
Fig. 68 Thailand key country dynamics
Fig. 69 Thailand market estimates and forecasts, 2018 - 2030
Fig. 70 South Korea key country dynamics
Fig. 71 South Korea market estimates and forecasts, 2018 - 2030
Fig. 72 Australia key country dynamics
Fig. 73 Australia market estimates and forecasts, 2018 - 2030
Fig. 74 Latin America market estimates and forecasts, 2018 - 2030
Fig. 75 Brazil key country dynamics
Fig. 76 Brazil market estimates and forecasts, 2018 - 2030
Fig. 77 Mexico key country dynamics
Fig. 78 Mexico market estimates and forecasts, 2018 - 2030
Fig. 79 Argentina key country dynamics
Fig. 80 Argentina market estimates and forecasts, 2018 - 2030
Fig. 81 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 82 South Africa key country dynamics
Fig. 83 South Africa market estimates and forecasts, 2018 - 2030
Fig. 84 Saudi Arabia key country dynamics
Fig. 85 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 86 UAE key country dynamics
Fig. 87 UAE market estimates and forecasts, 2018 - 2030
Fig. 88 Kuwait key country dynamics
Fig. 89 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 90 Market share/ position of key market players

Companies Mentioned

bioMérieux SA
BD
Danaher
Abbott
Hologic, Inc.
F. Hoffmann-La Roche Ltd
Bruker
Bio-Rad Laboratories, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	120
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 4.57 Billion
Forecasted Market Value ( USD ) by 2030	$ 6.6 Billion
Compound Annual Growth Rate	5.3%
Regions Covered	Global
No. of Companies Mentioned	8

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5800EUR$5,950USD£4,832GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6774EUR$6,950USD£5,644GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8724EUR$8,950USD£7,268GBP

Clinical Microbiology Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Clinical Microbiology Market by Product, Specimen Type, End-User, Application - Global Forecast 2025-2030

Clinical Microbiology Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product; Application; and End-User

Clinical Microbiology Market Size, Share & Trends by Application (Pharma, Food, Clinical,Manufacturing, Environment), Disease (Respiratory Disease, Blood Stream, GIT, UTI), Product (Instrument, Analyzer, Reagent), End User, and Region - Forecast to 2029

Clinical Microbiology Instruments and Reagents - Global Strategic Business Report

Clinical Microbiology Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)